• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CGC

    Canopy Growth Corporation

    Subscribe to $CGC
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

    IPO Year:

    Exchange: NYSE

    Website: canopygrowth.com

    Recent Analyst Ratings for Canopy Growth Corporation

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    12/22/2021$19.00 → $10.00Neutral → Underperform
    B of A Securities
    12/20/2021$11.00 → $7.00Neutral → Underweight
    Piper Sandler
    See more ratings

    Canopy Growth Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canopy Growth Drives Innovation in High-Demand Segments With Latest Product Launches

      Offerings reflect a focused format strategy in Canada's adult-use market Vapes, high-THC flower, pre-roll joints, and edibles introduced across core brands Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched a series of product innovations targeting Canada's fastest-growing adult-use categories.1 The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20

      5/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

      New Brand Features Premium Genetics, Selected for Potency, Terpenes, and Consistency Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a r

      4/2/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Strengthens Balance Sheet with Optional Early Prepayment to Reduce Term Loan by US$100 Million

      Early Prepayment Reduces Annual Interest Expense by US$13 Million, Extends Maturity of Term Loan to September 2027 This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated June 6, 2024 to its short form base shelf prospectus dated February 28, 2025 Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US

      4/1/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Wana Brands Brings Hemp-Derived THC Edibles to Texas

      BOULDER, Colo., March 17, 2025 /PRNewswire/ -- Wana Brands, North America's leading edibles provider and a subsidiary of Canopy USA LLC ("Canopy USA"), is thrilled to announce the launch of its hemp-derived Delta-9 THC gummies in Texas, marking the 22nd state where Wana gummies are available. This strategic expansion underscores Wana's commitment to delivering safe, reliable cannabis products that empower consumers to take control of their plant-powered wellness journey. "Wana's expansion into Texas comes at a pivotal time as the state's cannabis landscape continues to evolve,

      3/17/25 10:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Wana Brands Brings THC-Infused Sparkling Hemp Beverages to Total Wine & More Stores Nationwide

      Strategic Partnership Increases Consumer Availability for Premium Cannabis Beverages BOULDER, Colo., March 12, 2025 /PRNewswire/ -- Wana Brands, North America's leading edibles provider and a subsidiary of Canopy USA LLC ("Canopy USA"), today announced that Wana Beverages are now available at Total Wine & More locations nationwide, highlighting the increasing consumer demand for health-conscious, zero-proof alcohol alternatives. "For more than a decade, Wana has been at the forefront of cannabis formulation, delivering carefully crafted, science-backed products that consumers

      3/12/25 9:01:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Establishes New US$200 Million At-The-Market Program

      Net proceeds expected to be used for corporate purposes including paying down debt, strengthening the Company's cash position, and supporting strategic M&A SMITHS FALLS, ON, Feb. 28, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has established a new at-the-market equity program (the "ATM Program") that allows Canopy Growth to issue and sell up to US$200 million (or its Canadian dollar equivalent) of common shares of the Company ("Common Shares") from treasury from time to time in concurrent public offeri

      2/28/25 5:18:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Entry of Tweed Brand to German Medical Cannabis Market

      Four new Tweed strains available through an agreement with Portugal-based Gro-Vida Tweed Glitter Bomb strain launched in December 2024 through an agreement with German-based Cansativa SMITHS FALLS, ON, Feb. 27, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has officially launched its Tweed brand in the German medical cannabis market, including the availability of four new Tweed strains grown in the EU through an agreement with Gro-Vida S.A (Gro-Vida), a Portuguese medical cannabis cultivator.

      2/27/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Feb. 14, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      2/14/25 6:18:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Expands Deep Space Propulsion Beverage Lineup with Two New Flavours: Rocket Root Beer and Charged Cream Soda

      Together with Blue Sourberry and Altitude Lemon Lime, Deep Space Propulsion Continues to Pioneer the High-Potency Cannabis Beverage Category with its Expanded Portfolio of Innovative Flavours SMITHS FALLS, ON, Feb. 13, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today the expansion of its Deep Space Propulsion beverage lineup with two new flavours: Rocket Root Beer and Charged Cream Soda. Proudly developed in Canada, these innovative takes on classic flavours join Blue Sourberry and Altitude Lemon Lime, rounding out a portfol

      2/13/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results

      Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year   Record quarter for Canada medical cannabis with net revenue increasing 16%; international markets cannabis net revenue grew 14% year-over-year    Successfully launched Claybourne infused pre-rolls across Canada, Claybourne rose to #3 market share in the infused pre-roll category in British Columbia and Ontario after 6 weeks in market1 SMITHS FALLS, ON, Feb. 7, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the third fiscal quarter ended December 31, 2024 ("Q3 FY2025"). All financial information in this press

      2/7/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    Canopy Growth Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yanofsky Theresa sold $1,844 worth of shares (2,004 units at $0.92), decreasing direct ownership by 9% to 20,199 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:17:13 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lazzarato David Angelo sold $2,764 worth of shares (3,004 units at $0.92), decreasing direct ownership by 12% to 22,886 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:16:37 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $1,851 worth of shares (2,012 units at $0.92), decreasing direct ownership by 18% to 9,272 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:15:15 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Mongeau Luc was granted 50,000 shares, increasing direct ownership by 650% to 57,687 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      2/13/25 4:57:34 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $5,351 worth of shares (2,004 units at $2.67), decreasing direct ownership by 15% to 11,284 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      1/3/25 4:16:42 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Yanofsky Theresa sold $5,329 worth of shares (1,996 units at $2.67), decreasing direct ownership by 8% to 22,203 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      1/3/25 4:16:08 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lazzarato David Angelo sold $8,026 worth of shares (3,006 units at $2.67), decreasing direct ownership by 10% to 25,890 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      1/3/25 4:15:20 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Mongeau Luc sold $5,351 worth of shares (2,004 units at $2.67), decreasing direct ownership by 15% to 11,277 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      1/3/25 4:15:44 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $9,875 worth of shares (1,995 units at $4.95), decreasing direct ownership by 13% to 13,288 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      10/2/24 4:25:41 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Yanofsky Theresa sold $9,836 worth of shares (1,987 units at $4.95), decreasing direct ownership by 8% to 24,199 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      10/2/24 4:24:21 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    Canopy Growth Corporation SEC Filings

    See more
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      4/1/25 7:54:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:19:22 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B5 filed by Canopy Growth Corporation

      424B5 - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:17:50 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      2/7/25 7:06:45 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Canopy Growth Corporation

      10-Q - Canopy Growth Corp (0001737927) (Filer)

      2/7/25 6:45:33 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      12/10/24 4:42:38 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B7 filed by Canopy Growth Corporation

      424B7 - Canopy Growth Corp (0001737927) (Filer)

      12/10/24 4:35:43 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      12/9/24 4:15:33 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      11/26/24 4:15:35 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      11/8/24 7:10:18 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    Canopy Growth Corporation Financials

    Live finance-specific insights

    See more

    Canopy Growth Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Canopy Growth Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Feb. 14, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      2/14/25 6:18:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results

      Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year   Record quarter for Canada medical cannabis with net revenue increasing 16%; international markets cannabis net revenue grew 14% year-over-year    Successfully launched Claybourne infused pre-rolls across Canada, Claybourne rose to #3 market share in the infused pre-roll category in British Columbia and Ontario after 6 weeks in market1 SMITHS FALLS, ON, Feb. 7, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the third fiscal quarter ended December 31, 2024 ("Q3 FY2025"). All financial information in this press

      2/7/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Third Quarter Fiscal 2025 Financial Results on February 7, 2025

      SMITHS FALLS, ON, Jan. 24, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2025 ended December 31, 2024 before financial markets open on February 7, 2025. Following the release of its third quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Judy Hong, CFO on February 7 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://app.webinar.net/yY1K7LrWq9O

      1/24/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results

      Storz & Bickel net revenue increased 32% year-over-year in Q2 FY2025 Continued growth across medical cannabis businesses, with net revenue increasing year-over-year by 16% in Canada and 12% in international markets   Further improved balance sheet with early prepayment reducing senior secured term loan by US$100MM SMITHS FALLS, ON, Nov. 8, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the second quarter ended September 30, 2024 ("Q2 FY2025"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

      11/8/24 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Second Quarter Fiscal 2025 Financial Results on November 8, 2024

      SMITHS FALLS, ON, Oct. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2025 ended September 30, 2024 before financial markets open on November 8, 2024. Following the release of its second quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on November 8, 2024 at 10 AM Eastern Time. Webcast Information A live audio webcast will be available at: https://app.webinar.net/NXnR9dNY

      10/25/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Aug. 23, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      8/23/24 6:18:00 AM ET
      $CGC
      $TD
      Medicinal Chemicals and Botanical Products
      Health Care
      Commercial Banks
      Finance
    • Canopy Growth Reports First Quarter Fiscal Year 2025 Financial Results

       Focus on profitable revenue generation delivered 67% increase in gross profit year-over-year Record quarter for Canada Medical Cannabis with Net Revenue increasing 20% year-over-year and 6th consecutive quarter of growth Extended maturity of senior secured term loan to December 18, 2026 with an option to further extend to September 18, 2027 SMITHS FALLS, ON, Aug. 9, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the first quarter ended June 30, 2024 ("Q1 FY2025"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

      8/9/24 7:15:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report First Quarter Fiscal 2025 Financial Results on August 9, 2024

      SMITHS FALLS, ON, July 26, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2025 ended June 30, 2024 before financial markets open on August 9, 2024. Following the release of its first quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on August 9, at 10 AM Eastern Time. Webcast Information A live audio webcast will be available at: https://app.webinar.net/Lm5q6QW1Apv Replay Infor

      7/26/24 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses

      Storz & Bickel® delivered its best Q4 revenue quarter, with net revenue increasing 43% as compared to Q4 2023 Canada medical cannabis net revenue increased 16% in Q4 FY2024 and 10% in FY2024 year-over-year            Canada cannabis Cost of Goods Sold decreased by 54% in FY2024 versus FY2023 Following recent balance sheet actions, the Company has no material debt obligation due until March 20261 SMITHS FALLS, ON, May 30, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy", "Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis, today announced its financial results for the fourth quarter and fiscal year

      5/30/24 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Fourth Quarter and Fiscal Year 2024 Financial Results on May 30, 2024

      SMITHS FALLS, ON, May 16, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis, will release its financial results for the fourth quarter and fiscal year 2024 ended March 31, 2024 before financial markets open on May 30, 2024. Following the release of its fourth quarter and fiscal year 2024 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on May 30, at 10 AM Eastern Time. Webcast Information A li

      5/16/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Bernstein

      Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

      4/4/23 9:09:41 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Canopy Growth with a new price target

      Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

      11/2/22 6:11:10 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Canopy Growth from Sell to Hold

      10/26/22 7:36:52 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth downgraded by BMO Capital Markets

      BMO Capital Markets downgraded Canopy Growth from Market Perform to Underperform

      6/8/22 7:08:31 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth downgraded by Barclays

      Barclays downgraded Canopy Growth from Equal Weight to Underweight

      3/22/22 7:43:30 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Barclays reiterated coverage on Canopy Gwth with a new price target

      Barclays reiterated coverage of Canopy Gwth with a rating of Equal-Weight and set a new price target of $9.00 from $14.00 previously

      3/1/22 9:44:53 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cantor Fitzgerald reiterated coverage on Canopy Gwth with a new price target

      Cantor Fitzgerald reiterated coverage of Canopy Gwth with a rating of Neutral and set a new price target of $11.00 from $9.60 previously

      2/18/22 10:05:22 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth downgraded by BofA Securities

      BofA Securities downgraded Canopy Growth from Neutral to Underperform

      12/22/21 7:24:22 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Gwth downgraded by B of A Securities with a new price target

      B of A Securities downgraded Canopy Gwth from Neutral to Underperform and set a new price target of $10.00 from $19.00 previously

      12/22/21 7:13:32 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Canopy Growth from Neutral to Underweight and set a new price target of $7.00 from $11.00 previously

      12/20/21 7:12:22 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/19/24 5:00:49 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      11/3/23 4:30:53 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/20/23 4:35:52 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/14/23 5:32:26 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      10/26/22 4:58:01 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/19/22 4:30:53 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/1/22 4:31:01 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/29/21 4:46:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    Canopy Growth Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Canopy USA Announces Appointment of Mr. M. Brooks Jorgensen as President

      A cannabis and beverage alcohol industry executive with more than 25 years of experience, Mr. Jorgensen will lead the unified Canopy USA organization forward with a focus on driving profitable growth across the U.S. With the completed acquisitions of Acreage, Wana, and Jetty, Canopy USA now enters a new chapter of growth across key segments including flower, edibles, vapes, extracts, and through an established retail presence in high potential markets across the Midwest and Northeast BOULDER, Colo., January 6, 2025 /PRNewswire/ - Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. c

      1/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General Meeting

      SMITHS FALLS, ON, Sept. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce today the voting results from its annual general meeting of shareholders held on September 24, 2024 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 1, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of the direc

      9/25/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General Meeting

      Shareholders now have until September 24, 2024 at 9:00 a.m. (Eastern Time) to submit votes to help ensure a quorum is achieved Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] SMITHS FALLS, ON, Sept. 20, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general meeting of shareholders (the "Meeting") to September 24, 2024 at 9:00 a.m. (Eastern time). The Meeting will be held later the same day, at 1:00 p.m.

      9/20/24 4:45:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Urges Shareholders to Cast their Vote for the Upcoming Annual Meeting Today

      Shareholders are Encouraged to Vote Well in Advance of the Proxy Deadline on September 20, 2024 at 1:00 p.m. (Eastern time) Company Releases Q&A About Annual Meeting Quorum Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] SMITHS FALLS, ON, Sept. 11, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today urges its shareholders to vote ahead of the upcoming annual general meeting of shareholders (the "Meeting") on September 24, 2024 at 1:00 pm (Eastern time). The Board of Directors of Canopy Growth recommends shareho

      9/11/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Mailing and Filing of Annual General Meeting Materials

      Canopy Growth's AGM to be held in a virtual-only format on Tuesday, September 24, 2024 at 1:00 PM ET.Voting is important and easy; shareholders are encouraged to vote now.Canopy Growth shareholders with a 16-digit control number can vote online at http://proxyvote.com, by phone at 1-800-474-7493, and by mail using the enclosed pre–paid envelope.For more information, shareholders should contact Canopy Growth's strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, at 1-877-452-7184 (1–416–304–0211 for collect calls outside North America) or by email at [email protected] FALLS, ON, Aug. 13, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy G

      8/13/24 4:30:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General and Special Meeting of Shareholders

      SMITHS FALLS, ON, Sept. 26, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading diversified cannabis company, today announced the voting results from its annual general and special meeting of shareholders held on September 25, 2023 (the "Meeting"). A total of 350,593,653 common shares of the Company (the "Shares"), representing 48.88% of the issued and outstanding Shares, were voted in connection with the Meeting by the Company's shareholders and proxy holders. All of the matters put forward before the Compa

      9/26/23 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Cease Funding BioSteel Business Unit Furthering Business Transformation and Focus on North American Cannabis Leadership

      BioSteel filing immediately eliminates significant cash burn for Canopy Growth and provides for an orderly realization of value of BioSteel's assets through a sale process As the senior secured lender to BioSteel, Canopy Growth expects to recover proceeds from the anticipated sale process  Management reaffirms its expectation to achieve positive Adjusted EBITDA in all remaining business units exiting FY2024, as the Company focuses on driving growth in its Canadian and U.S. cannabis businesses to position itself as an industry leader in North America SMITHS FALLS, ON, Sept. 14, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today annou

      9/14/23 8:44:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Appoints PKF O'Connor Davies as Auditor

      SMITHS FALLS, ON, June 29, 2023 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today the appointment of PKF O'Connor Davies, LLP ("PKFOD") as its independent registered public accounting firm for the 2024 fiscal year and accepted the resignation of KPMG LLP ("KPMG"). "This change has been underway for some time and reflects a joint decision between Canopy Growth and KPMG. We are pleased to welcome PKFOD, which has specific experience in supporting clients in the cannabis industry as our accounting firm for fiscal 2024. Go

      6/29/23 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Appoints PKF O'Connor Davies as Auditor

      SMITHS FALLS, ON, June 29, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today the appointment of PKF O'Connor Davies, LLP ("PKFOD") as its independent registered public accounting firm for the 2024 fiscal year and accepted the resignation of KPMG LLP ("KPMG"). "This change has been underway for some time and reflects a joint decision between Canopy Growth and KPMG. We are pleased to welcome PKFOD, which has specific experience in supporting clients in the cannabis industry as our accounting firm for fiscal 2

      6/29/23 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General and Special Shareholder Meeting

      SMITHS FALLS, ON, Sept. 16, 2022 /PRNewswire/ - Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) ("Canopy Growth" or the "Company") today announced the voting results from its annual general and special meeting of shareholders held on September 15, 2022 (the "Meeting"). A total of 256,426,802 common shares of the Company, representing 53.42% of the issued and outstanding common shares of the Company, were voted in connection with the Meeting by shareholders and proxy holders. All of the matters put forward before the Company's shareholders for consideration and approval, as s

      9/16/22 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care